Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
10.80
+0.17 (1.60%)
At close: Sep 28, 2026, 4:00 PM EDT
10.88
+0.08 (0.74%)
Pre-market: Sep 29, 2026, 8:57 AM EDT

Novavax Revenue

Novavax had revenue of $56.70M in the quarter ending June 30, 2026, a decrease of -76.30%. This brings the company's revenue in the last twelve months to $413.80M, down -61.64% year-over-year. In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth.

Revenue (ttm)
$413.80M
Revenue Growth
-61.64%
P/S Ratio
4.31
Revenue / Employee
$552,465
Employees
749
Market Cap
1.78B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020475.60M456.94M2,448.48%
Dec 31, 201918.66M-15.63M-45.57%
Dec 31, 201834.29M3.11M9.98%
Dec 31, 201731.18M15.82M103.06%
Dec 31, 201615.35M-20.90M-57.65%
Dec 31, 201536.25M5.59M18.24%
Dec 31, 201430.66M9.74M46.59%
Dec 31, 201320.92M-1.16M-5.26%
Dec 31, 201222.08M7.39M50.30%
Dec 31, 201114.69M14.35M4,182.22%
Dec 31, 2010343.00K18.00K5.54%
Dec 31, 2009325.00K-739.00K-69.45%
Dec 31, 20081.06M-449.00K-29.68%
Dec 31, 20071.51M-225.00K-12.95%
Dec 31, 20061.74M-3.61M-67.47%
Dec 31, 20055.34M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Vir Biotechnology303.23M
Mesoblast120.25M
Xencor104.97M
Septerna98.88M
Intellia Therapeutics59.51M
Zymeworks37.13M
Nanobiotix13.15M
Absci1.56M
Revenue Rankings